Skip to main content
Premium Trial:

Request an Annual Quote

Opko Expands Prostate Cancer Biomarker Licensing Deal as Part of Commercialization Plan

Premium

Opko Health said this week that it has expanded a licensing deal with Finnish biotech firm Artic Partners for prostate cancer protein biomarkers that it announced in January (PM 1/30/2012).

That initial license gave Opko rights to two biomarkers in the kallikrein family that can be used with prostate specific antigen to predict initial biopsy results in men suspected of having prostate cancer. With the expansion of the agreement, Opko has exercised "a right of first refusal to secure additional proprietary information, patents, know-how, property, and technology associated with time-resolved fluorescence detection technology" applicable to these markers, it said in a statement.

The company added that it "will pursue commercialization of the [markers] on platforms for use in a laboratory setting as well as the point of care."

Although PSA is commonly used as a prostate cancer biomarker, it is not specific for the disease, leading to an estimated 750,000 unnecessary prostate biopsies in the US annually. The Opko test will combine PSA with the two kallikrein markers in hopes of improving the accuracy of the test.

A study published in BMC Medicine in 2008 showed that the addition of the markers improved the predictive value of a standard clinical prostate cancer exam – consisting of age, PSA measurement, and a digital rectal exam – to an area under the curve of .84 from an AUC of .72.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.